The beneficial effects of lipid-lowering therapy with xuezhikang on cardiac events and total mortality in coronary heart disease patients with or without hypertension: a random, double-blinded, placebo controlled clinical trial.
- Author:
Bao-min DU
1
;
Zong-liang LU
;
Zuo CHEN
;
Yang-feng WU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Coronary Disease; drug therapy; mortality; Double-Blind Method; Drugs, Chinese Herbal; therapeutic use; Humans; Hypertension; complications; drug therapy; mortality; Hypolipidemic Agents; therapeutic use; Lipids; blood; Middle Aged; Phytotherapy; Survival Rate
- From: Chinese Journal of Cardiology 2006;34(10):890-894
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate whether lipid-lowering therapy with Xuezhikang can reduce the risk of cardiac events and total mortality in coronary heart disease (CHD) patients with or without hypertension.
METHODSIn this random, double-blinded, placebo controlled clinical trial, 2704 patients with hypertension and 2166 patients without hypertension were enrolled and capsule Xuezhikang 0.6 g Bid or placebo on the top of conventional therapy without other lipid-lowering drugs. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and total mortality.
RESULTSCompared to placebo group, the incidence of cardiac events was reduced by 44.0% (P<0.0001) and 47.4% (P<0.0001) respectively in CHD patients with or without hypertension, and the total mortality was lowered by 35.8% (P=0.0012) and 28.6% (P=0.0737) respectively in CHD patients with or without hypertension. There was no significant difference in side effects between study groups.
CONCLUSIONXuezhikang can reduce the cardiac events and mortality in CHD patients with or without hypertension.
